David Stanton
Stock Analyst at Jefferies
(4.38)
# 1,268
Out of 4,978 analysts
243
Total ratings
50.8%
Success rate
14.2%
Average return
Main Sectors:
Stocks Rated by David Stanton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: IMM Immutep Limited | Upgraded: Buy | $0.04 → $0.08 | $0.05 | +77.78% | 9 | Sep 15, 2026 | |
| ASX: TLX Telix Pharmaceuticals Limited | Reiterated: Buy | $29.30 → $30.00 | $17.40 | +72.41% | 25 | Sep 14, 2026 | |
| ASX: MVF Monash IVF Group Limited | Reiterated: Buy | $0.83 → $0.80 | $0.78 | +2.30% | 12 | Sep 1, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Reiterated: Buy | $40.80 → $39.30 | $8.21 | +378.68% | 12 | Aug 30, 2026 | |
| ASX: MSB Mesoblast Limited | Reiterated: Buy | $3.00 → $2.90 | $2.07 | +40.44% | 17 | Aug 30, 2026 | |
| ASX: RHC Ramsay Health Care Limited | Reiterated: Hold | $39.80 → $48.50 | $55.43 | -12.50% | 13 | Aug 30, 2026 | |
| ASX: SIG Sigma Healthcare Limited | Reiterated: Buy | $3.30 → $3.20 | $2.61 | +22.84% | 18 | Aug 30, 2026 | |
| ASX: IDX Integral Diagnostics Limited | Reiterated: Buy | $3.50 → $3.30 | $2.33 | +41.63% | 11 | Aug 27, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Reiterated: Buy | $29.40 → $28.90 | $20.80 | +38.94% | 19 | Aug 27, 2026 | |
| ASX: COH Cochlear Limited | Reiterated: Hold | $128.40 → $144.75 | $136.51 | +6.04% | 20 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $119.00 → $146.50 | $176.60 | -17.04% | 25 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.38 → $0.41 | $0.45 | -7.87% | 18 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $188.25 → $196.95 | $166.32 | +18.42% | 6 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $23.00 → $21.00 | $19.71 | +6.54% | 22 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 → $5.60 | $2.03 | +175.86% | 12 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.41 | n/a | 1 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.75 | n/a | 3 | Apr 8, 2021 |
Immutep Limited
Sep 15, 2026
Upgraded: Buy
Price Target: $0.04 → $0.08
Current: $0.05
Upside: +77.78%
Telix Pharmaceuticals Limited
Sep 14, 2026
Reiterated: Buy
Price Target: $29.30 → $30.00
Current: $17.40
Upside: +72.41%
Monash IVF Group Limited
Sep 1, 2026
Reiterated: Buy
Price Target: $0.83 → $0.80
Current: $0.78
Upside: +2.30%
Clinuvel Pharmaceuticals Limited
Aug 30, 2026
Reiterated: Buy
Price Target: $40.80 → $39.30
Current: $8.21
Upside: +378.68%
Mesoblast Limited
Aug 30, 2026
Reiterated: Buy
Price Target: $3.00 → $2.90
Current: $2.07
Upside: +40.44%
Ramsay Health Care Limited
Aug 30, 2026
Reiterated: Hold
Price Target: $39.80 → $48.50
Current: $55.43
Upside: -12.50%
Sigma Healthcare Limited
Aug 30, 2026
Reiterated: Buy
Price Target: $3.30 → $3.20
Current: $2.61
Upside: +22.84%
Integral Diagnostics Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.50 → $3.30
Current: $2.33
Upside: +41.63%
Neuren Pharmaceuticals Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $29.40 → $28.90
Current: $20.80
Upside: +38.94%
Cochlear Limited
Aug 20, 2026
Reiterated: Hold
Price Target: $128.40 → $144.75
Current: $136.51
Upside: +6.04%
Aug 20, 2026
Reiterated: Hold
Price Target: $119.00 → $146.50
Current: $176.60
Upside: -17.04%
Aug 20, 2026
Reiterated: Hold
Price Target: $0.38 → $0.41
Current: $0.45
Upside: -7.87%
Aug 20, 2026
Reiterated: Hold
Price Target: $188.25 → $196.95
Current: $166.32
Upside: +18.42%
Aug 20, 2026
Reiterated: Hold
Price Target: $23.00 → $21.00
Current: $19.71
Upside: +6.54%
Jul 28, 2026
Reiterated: Buy
Price Target: $5.00 → $5.60
Current: $2.03
Upside: +175.86%
Dec 6, 2022
Downgraded: Hold
Price Target: n/a
Current: $14.41
Upside: n/a
Apr 8, 2021
Downgraded: Hold
Price Target: n/a
Current: $13.75
Upside: n/a